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1. Introduction 
The dysmetabolic syndrome (DMS) reunites a cluster of interrelated and important risk 
factors and/or medical conditions or disorders which act and worsen each other, aggravate 
and provoke each other, promoting the development of atherosclerotic vascular disease and 
type 2 diabetes (DM).  
Although it has been termed „a syndrome or a disease-state”, the prevalence of metabolic 
syndrome has risen dramatically in all societies over the past two decades; therefore, DMS 
should be analyzed as „an educational concept that focuses attention on complex 
multifactorial health problems”, but in relation „to four key areas: pathophysiology, 
epidemiology, clinical work and public health” (Ford et all., 2002; Simmons et all., 2010). 
This aspect must be well deepened by doctors and understood by patients, because the 
patients with DMS are at a much higher risk for many and serious medical conditions 
(atherogenic dyslipidemia, elevated blood pressure, elevated plasma glucose, 
proinflammatory and prothrombotic states, and so on).  
This review evaluates the multiple similarities and differences between several concepts and 
definitions of DMS, in an attempt to clarify its practical and clinical usefulness, amid many 
exciting controversies. The clinical significance of DMS, as a distinct entity, has been 
debated in the past years. Initially, DMS was scarcely used as a practical tool for clinical 
management, educational concept or pre-morbid condition, until 1988, when GM Reaven 
brought it to the attention of clinicians and theorists in “Banting Lecture”; thus, GM Reaven 
remains the main author who has developed and strengthened this „clinical and 
pathological concept”, identifying insulin resistance as the central pathophysiologic feature 
(Reaven, 1988). 
DMS is known under many names: „Metabolic syndrome” (World Health Organisation 
[WHO], 1998; National Cholesterol Education Program [NCEP], 2002; International Diabetes 
Federation [IDF], 2005), „Insulin resistance syndrome”, „Dysmetabolic syndrome”, 
„Cardiometabolic syndrome”, „Syndrome X” (Reaven, 1988), „Plurametabolic syndrome”, 
„Deadly Quartet: upper-body obesity, glucose intolerance, hypertriglyceridemia, and 
hypertension” (Kaplan, 1989), ”Atherometabolic Syndrome”, „Sindrom dismetabopres” 
(Buşoi G, 2005), „CHAOS” (in Australia), and so on. 
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2. History 
The history of DMS was not an easy one; we will present, in chronological order, the most 
important events (Isomaa et al., 2001). 
Between 1920-1923, Kylin (as cited in Lau, 2009), a Swedish physician, described for the first 
time a constellation of metabolic disturbance and the clustering of hypertension, 
hyperglycemia, and gout. After Kylin, J Vague, from the University of Marseille, reported 
that body fat topography, respectively upper-body obesity, causes the predisposition to 
diabetes mellitus, atherosclerosis, gout, and renal calculi, and that its anatomical 
distribution differs according to gender. Vague used the term "android obesity" to define the 
pattern of fat distribution with an accumulation of adipose tissue over the trunk and the 
term “gynoid obesity" for adipose tissue that accumulates mostly around the hips and 
thighs, commonly found in women (Vague et al., 1947). As the research continued, after 
1960, a link between obesity, insulin-resistance and related complications was suggested. 
Albrink and Meigs reported an association between trunk fat and hypertriglyceridemia 
(Meigs et al., 2003). In 1975-1977, Haller used the term "metabolic syndrome" for an 
association of obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, and hepatic 
steatosis, and describes the additional role of these risk factors on the cardiovascular disease 
(CVD) (Haller, 1977). In 1977-1978, Singer and Phillips developed the concept that risk 
factors for myocardial infarction, respectively a "constellation of associated abnormalities" 
(i.e. glucose intolerance, hyperinsulinemia, hypercholesterolemia, hypertriglyceridemia, and 
hypertension) are associated with CVD, aging, obesity, sex hormones, and other clinical 
states (Singer, 1977; Phillips, 1978). In 1988, Reaven, describes “Syndrome X” in his famous 
Banting Lecture; this is a critical moment, subject to many controversies in the literature; 
more and more risk factors (RF) (hypertension, hyperglycemia, glucose intolerance, elevated 
triglycerides, and low HDL-cholesterol), as well as many metabolic disturbances, especially 
insulin resistance, are incriminated in the pathogeny of CVD (Reaven, 1988). In 2005, Kahn 
draws attention to several unresolved questions about the metabolic syndrome, many of 
them still unresolved even now: 
- Metabolic syndrome name? 
- Existence of metabolic syndrome? 
- More than some of its parts? 
- Metabolic sindrome vs. prediabetes & type 2 diabetes 
- Diagnostic utility? Pathogenesis? Clinical utility? 
3. Definitions of dysmetabolic syndrome 
In 1998-1999, WHO defines metabolic syndrome (MS) as a clustering of arterial 
hypertension, dyslipidemia, obesity with high waist to hip ratio, microalbuminuria, glucose 
intolerance or insulin resistance, or type 2 diabetes; at the same time, it recognizes „CVD as 
the primary outcome of the metabolic syndrome’’ (table 1). 
The criteria for the diagnosis of MS are: the presence of one of diabetes mellitus, impaired 
glucose tolerance, impaired fasting glucose or insulin resistance, AND two of the following: 
1. blood pressure ≥ 140/90 mmH 
2. dyslipidemia: triglycerides (TG) ≥ 1.695 mmol/L and high-density lipoprotein 
cholesterol (HDL-C) ≤ 0.9 mmol/L (in males) or ≤ 1.0 mmol/L (in females); 
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Parameters NCEP ATP3 2005 IDF 2005 EGIR 1999 WHO 1999 AACE 2003 
Required  Waist ≥94 cm 
(men) or ≥80 
cm (women)* 
Insulin resistance or 
fasting 
hyperinsulinemia in 
top 25 percent 
Insulin 
resistance in 
top 25 %; 
glucose ≥6.1 
mmol/L (110 
mg/dL); 2-
hour glucose 
≥7.8 mmol/L 
(140 mg/dL) 
High risk of 
insulin 
resistanceΔ or 
BMI ≥25 kg/m2 
or waist ≥102 cm 
(men) or ≥88 cm 
(women) 
Nr. of 
abnormalities 
≥3 of: And ≥2 of: And ≥2 of: And ≥2 of: And ≥2 of: 
Glucose ≥5.6 mmol/L (100 
mg/dL) or drug 
treatment for 
elevated blood 
glucose 
≥5.6 mmol/L 
(100 mg/dL) 
or 
diagnosediabe
tes 
6.1-6.9 mmol/ (110-125 
mg/dL) 
  ≥6.1 mmol/L 
(110 mg/dL); ≥2-
hour glucose 7.8 
mmol/L (140 
mg/dL) 
HDL cholesterol <1.0 mmol/L (40 
mg/dL) (men); 
<1.3 mmol/L (50 
mg/dL) (women) 
or drug treatment 
for low HDL-C◊ 
<1.0 mmol/L 
(40 mg/dL) 
(men); <1.3 
mmol/L (50 
mg/dL) 
(women) or 
drug 
treatment for 
low HDL-C 
<1.0 mmol/L (40 
mg/dL) 
<0.9 mmol/L 
(35 mg/dL) 
(men); <1.0 
mmol/L (40 
mg/dL) 
(women) 
<1.0 mmol/L (40 
mg/dL) (men); 
<1.3 mmol/L (50 
mg/dL) 
(women) 
TGs ≥1.7 mmol/L (150 
mg/dL) or drug 
treatment for 
elevated 
triglycerides◊ 
≥1.7 mmol/L 
(150 mg/dL) 
or drug 
treatment for 
high TGs 
or ≥2.0 mmol/L (180 
mg/dL) or drug 
treatment for 
dyslipidemia 
or ≥1.7 
mmol/L (150 
mg/dL) 
≥1.7 mmol/L 
(150 mg/dL) 
Obesity Waist ≥102 cm 
(men) or ≥88 cm 
(women)§ 
Waist ≥94 cm (men) or 
≥80 cm (women) 
Waist/hip 
ratio >0.9 
(men) or >0.85 
(women) or 
BMI ≥30 
kg/m2 
  
HTA ≥130/85 mmHg or 
drug treatment for 
HTA 
≥130/85 
mmHg or 
drug 
treatment for 
HTA 
≥140/90 mmHg or 
drug treatment for 
hypertension 
≥140/90 
mmHg 
≥130/85 mmHg 
* For South Asia and Chinese patients, waist ≥90 cm (men) or ≥80 cm (women); for Japanese patients, 
waist ≥90 cm (men) or ≥80 cm (women).  
 Insulin resistance measured using insulin clamp.  
Δ High risk of being insulin resistant is indicated by the presence of at least one of the following: 
diagnosis of CVD, hypertension, polycystic ovary syndrome, non-alcoholic fatty liver disease or 
acanthosis nigricans; family history of Type 2 diabetes, hypertension of CVD; history of gestational 
diabetes or glucose intolerance; nonwhite ethnicity; sedentary lifestyle; BMI 25 kb/m2 or waist 
circumference 94 cm for men and 80 cm for women; and age 40 years.  
◊ Treatment with one or more of fibrates or niacin. § In Asian patients, waist ≥90 cm (men) or ≥80 cm 
(women). 
Table 1. Five current definitions of the metabolic syndrome (Meigs, 2006). 
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3. central obesity: waist:hip ratio > 0.90 (in males) and > 0.85 (in females), or body mass 
index > 30 kg/m2 ;  
4. microalbuminuria: urinary albumin excretion ratio ≥ 20 µg/min. or albumin:creatinine 
ratio ≥ 30 mg/g. 
We can see a potential disadvantage of the WHO criteria, namely the need for the routine 
assessment of the glycemic metabolism. (Simmons et al., 2010; Alberti & Zimmet, 1998).  
The European Group for the Study of Insulin Resistance (EGIR, 1999), designed to be used 
in non diabetics only, requires two or more of the following: 
1. central obesity: waist circumference ≥ 94 cm (male), ≥ 80 cm (female); 
2. dyslipidemia: TG ≥ 2.0 mmol/L and/or HDL-C < 1.0 mmol/L or treated for 
dyslipidemia; 
3. hypertension: blood pressure ≥ 140/90 mmHg or antihypertensive medication; 
4. fasting plasma glucose (FPG) ≥ 6.1 mmol/L (table 1).  
In 2001-2002, the National Cholesterol Education Program and Adult Treatment Panel 
(ATPIII) provides a clinical definition of metabolic syndrome, “a multiplex risk factor for 
cardiovascular disease (CVD) and identifies” six components of the metabolic syndrome 
that relate to CVD: abdominal obesity, atherogenic dyslipidemia, raised blood pressure, 
insulin resistance ± glucose intolerance, proinflammatory state, prothrombotic state”. It also 
states that “the presence of type 2 DM does not exclude a diagnosis of metabolic syndrome” 
and the definition does not require evidence of insulin or glucose abnormalities, although 
„abnormal glycemia is one of the criteria”. The US NCEP and ATP III require at least three 
of the following: 
1. central (abdominal) obesity: waist circumference ≥ 102 cm (40 inches) (male), ≥ 88 cm 
(35 inches) (female); 
2. dyslipidemia:  
- TG ≥ 150 mg/dL (1.7 mmol/L), or drug treatment for elevated triglycerides; 
- HDL-C < 40 mg/dL (1 mmol/L) (male), < 50 mg/dL (1,3 mmol/L) (female), or 
drug treatment for low HDL-C; 
3. blood pressure ≥ 130/85 mmHg, or drug treatment for elevated blood pressure; 
4. FPG ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated blood glucose (table 1).  
We can see that:  
- the WHO criteria consider both central obesity (“waist-to-hip ratio”) and overall obesity 
(defined by the “BMI”);  
- the NCEP ATP III criteria consider only central obesity (“waist circumference”),  
- the presence of type 2 DM does not exclude the diagnosis of metabolic syndrome; 
- elevated microalbuminuria is a component in the WHO definition, while it is not 
considered for NCEP ATP III (NCEPT ATPIII, 2001, 2002). 
In 2005, ADA (American Diabetes Association) and EASD (European Association for the 
Study of Diabetes) discourage the use of the term “metabolic syndrome” in the field 
literature, questioning “whether this constellation of clinical findings constitutes a 
syndrome” and “whether that constellation, in and of itself, is an entity of medical concern 
above and beyond the individual components”, and so on (Beaser & Levy, 2007). 
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The IDF (International Diabetes Federation) releases in 2005 the “Consensus worldwide 
definition” of the metabolic syndrome, which mentions the following criteria needed for the 
diagnosis: 
1. central obesity is an essential element (defined as waist circumference with 
race/ethnicity specific values) and any two of the following: 
2. raised triglycerides: > 150 mg/dL (1.7 mmol/L) or specific treatment for this lipid 
abnormality;  
3. reduced HDL cholesterol: < 40 mg/dL (1.03 mmol/L) in males, < 50 mg/dL (1.29 
mmol/L) in females, or specific treatment for this lipid abnormality; 
4. raised blood pressure: systolic BP > 130 mmHg or diastolic BP >85 mmHg, or treatment 
of previously diagnosed hypertension;  
5. raised fasting plasma glucose : > 100 mg/dL (5.6 mmol/L), or previously diagnosed 
type 2 diabetes. (table 1 and 2).  
It can be noted that: 
- if FPG > 5.6 mmol/L or 100 mg/dL, oral glucose tolerance test (OGTT) is strongly 
recommended, but is not necessary to define presence of the MS; 
- if BMI is > 30 kg/m², central obesity can be assumed and waist circumference does not 
need to be measured (Alberti et al., 2005, 2006). 
 
ADDITIONAL METABOLIC IDF CRITERIA (for research) 
Abnormal body fat distribution: 
- general body fat distribution, 
- central fat distribution (CT/MRI), 
- adipose tissue biomarkers: leptin, adiponectin, 
- liver fat content. 
Atherogenic dyslipidaemia (beyond elevated triglyceride and low HDL):
- ApoB (or non-HDL-C), 
- small LDL particles.
Dysglycaemia: Oral glucose tolerance test (OGTT).
Insulin resistance (other than elevated fasting glucose):
- fasting insulin/proinsulin levels, 
- insulin resistance, 
- elevated free fatty acids (fasting and during OGTT).
Vascular dysregulation (beyond elevated blood pressure):
- measurement of endothelial dysfunction, 
- microalbuminuria.
Proinflammatory state:
- elevated high sensitivity C-reactive protein, 
- elevated inflammatory cytokines (eg TNF-alpha, IL-6), 
- decrease in adiponectin plasma levels.
Prothrombotic state:
- fibrinolytic factors (PAI-1 etc), 
- clotting factors (fibrinogen etc).
Hormonal factors: pituitary-adrenal axis.
Table 2. IDF: Additional metabolic criteria (for research) -„platinum standard” definition 
(www.idf,org) 
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After a brief period of time, AHA (American Heart Association) and NHLB (National Heart, 
Lung, and Blood Institute) state the opposite and consider MS: 
- a “multidimensional risk condition” for both atherosclerotic cardiovascular disease 
(ASCVD) and type 2 diabetes; 
- as “multiple risk factors that are metabolically interrelated”; 
- as “multifactorial in origin, with underlying causes and exacerbating factors”. 
The confusion generated by AHA/NHLBI is clarified by AHA/Updated NCEP ATP III, 
which gives the following criteria of diagnosis:  
1. elevated waist circumference:  
- men — greater than 40 inches (102 cm); 
- women — greater than 35 inches (88 cm); 
2. elevated triglycerides - equal to or greater than 150 mg/dL (1.7 mmol/L);  
3. reduced HDL (“good”) cholesterol:  
- men — less than 40 mg/dL (1.03 mmol/L);  
- women — less than 50 mg/dL (1.29 mmol/L); 
4. elevated blood pressure:  
- equal to or greater than 130/85 mm Hg or  
- use of medication for hypertension; 
5. elevated fasting glucose:  
- equal to or greater than 100 mg/dL (5.6 mmol/L) or use of medication for 
hyperglycemia. 
The following notes are made:  
- lowering the threshold for abnormal fasting glucose to 100 mg/dL, corresponding to 
the ADA criteria for impaired fasting plasma glucose; 
- the inclusion of diabetes in the hyperglycemia trait definition;  
- the therapeutic control of dyslipidemia and arterial hypertension (table 1) (Grundy et 
al., 2004, 2005; Beilby, 2004). 
Following this statement, AACE (American Association of Clinical Endocrinologists) 
propose a “third set of clinical criteria for the insulin resistance syndrome”, in fact ‘’a hybrid 
of those of ATP III and WHO metabolic syndrome’’, but with „clinical value as a diagnosis”.  
As a disease entity, MS is recognized by the American Society of Endocrinology, NCEP, and 
WHO, among others. The above mentioned set has some complicated aspects:  
- it does not state the number of RF; 
- the diagnosis is left to clinical judgment; 
- the term „insulin resistance syndrome” is not applied when the patient has MD, but 
„high risk of being insulin resistant” is indicated by the presence of at least one of the 
following:  
- diagnosis of CVD, hypertension, polycystic ovary syndrome, non-alcoholic fatty 
liver disease or acanthosis nigricans;  
- family history of type 2 diabetes, hypertension or CVD;  
- history of gestational diabetes or glucose intolerance;  
- non-white ethnicity; sedentary lifestyle; BMI 25 kb/m2 or waist circumference 94 
cm for men and 80 cm for women; and  
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- age 40 years (table 1) (Kahn, 2005). 
Now the DMS has been recognized as a proinflammatory, prothrombotic state, with 
elevated levels of C-reactive protein, interleukin (IL)-6, and plasminogen activator inhibitor 
(PAI)-1, and so on. Therefore, in the near future, many other diagnostic criteria will arise; for 
example, if high-sensitivity c-reactive protein (hs-CRP) can be used as a marker to predict 
coronary vascular diseases in DMS and as a predictor for non-alcoholic fatty liver disease, in 
correlation with serum markers that indicate the disturbance of the lipid and glucose 
metabolism (Kogiso et al., 2009).  
These sets of defining criteria for DMS are similar but they also have many important 
differences (clinical, etiopathogenic, ethnical, geographical, and so on) (tables 1,2,3). In fact, 
these five definitions of DMS illustrate “its complexity and heterogeneity”, although they 
are not unanimously accepted. 
 
ATP III / IDF 
Atherogenic dyslipidemia 
Elevated blood pressure 
Elevated plasma glucose 
Prothrombotic state 
Proinflammatory state 
ADA / EASD 
Atherogenic dyslipidemia 
Prediabetes 
Elevated plasma glucose 
Prothrombotic state 
Proinflammatory state 
Table 3. Clustering or constellation of the metabolic risk factors (3+) in definition of the 
metabolic syndrome 
The DMS is an insulin-resistant state with a cluster of cardiovascular risk factors, including 
various combinations and substantial additional CV risk, which occur in the same 
individual, but the question is “how to integrate the DMS into concepts of insulin resistance, 
pre-diabetes, and type-2 diabetes”. Insulin resistance is a component of obesity, it favors the 
onset of type 2 DM and is found in many cases of hypertension and hypertriglyceridaemia 
with low levels of HDL-cholesterol (Reaven, 1988), in association with correlated metabolic 
abnormalities recognized as CV risk factors that are present prior to the onset of diabetes. If 
insulin resistance evolves with many other characteristics (abdominal obesity, dyslipidemia, 
hypertension, non-dipper pattern of blood pressure, salt sensitivity, glucose intolerance, 
history of gestational DM, increased PAI-1/ platelets and so on), can all of these be seen as 
cardiovascular RF in various combinations? Which and how many of these RF carry the 
greatest impact? (Johnson & Weinsstock, 2006). 
In all definitions of DMS, the abdominal adiposity is underlined and not the body weight. It 
is indeed the visceral adipocytes that are metabolically active, leading „to elevated plasma 
free fatty acids that result in elevated triglycerides and lower HDL cholesterol, and 
contribute to elevated plasma glucose”; is this explication enough to consider that this type 
of obesity is the RF with the greatest impact? (Beaser & Levy, 2005). 
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In addition to age, race, and weight are there other RF associated with an increased risk of 
DMS? Indeed, in NHANES III trial, other RF have emerged (postmenopausal status, 
smoking, low household income, high carbohydrate diet, no alcohol consumption, and 
physical inactivity); should these RF be included in the DMS? And when other RF for CVD 
will arise, which RF will not be components of the DMS? We should not forget that the 
notion of DMS ignores „other several strong risk factors” for cardiovascular disease (like 
cigarette smoking and elevated levels of low-density lipoprotein cholesterol, for example). 
(Palaniappan et al., 2004). 
Is the treatment of the DMS different, next to the treatment for each of its components? It is 
obvious that the presence of a DMS component will lead to its evaluation and optimal 
treatment, but it is also important to look for and evaluate all the individual components of 
DMS from all the definitions. If a patient has certain characteristics included in one of the 
definitions for DMS (large waist circumference, high triglycerides and high fasting glucose) 
and another patient has other characteristics (high blood pressure, low HDL, and high 
triglycerides), both of them will be diagnosed with DMS, but will they benefit from different 
therapeutic strategies? Because there is no unique mechanism for DMS, thereby there won’t 
be a unique treatment (Bayturan et al., 2010). 
If we accept that “the Framingham score for the risk” is a better “short-term” (10 year) risk 
tool, does it mean that the metabolic syndrome was meant to identify individuals at “higher 
long-term risk”? Are there other risk factors for CVD, which are not components of the 
metabolic syndrome, such as inflammatory markers, which may have equal or greater 
bearing on risk? (Grundy, 2006). Is the CVD risk associated with the metabolic syndrome 
higher than the sum of its individual components? (Sundstorm et al., 2006). 
The setting of diagnostic criteria for DMS is very difficult with numerous controversies and 
uncertainties. Therefore, is the DMS:  
1. a true syndrome? 
2. a simple collection of things with “an identifiable pattern” ? 
3. a clustering of certain signs and symptoms that tend to occur under certain 
circumstances? 
4. three or more related diagnostic entities associated with any morbid process? And so on 
(Kahn et al., 2005; Balta, 2010). 
This research showed that the SM is a most complex problem, a focus of much research and 
clinical interest, involving: 
- symptoms that are associated,  
- diseases that occur as a result of this condition, 
- multiple risk factors representing the factors of metabolic origin (table 4). 
Metabolic syndrome affects 44% of the U.S. population older than age 50; the percentage of 
women having the syndrome is higher than that of men; the age dependency of the 
syndrome's prevalence is seen in most populations around the world. The „clustering” of 
CV and metabolic abnormalities in the same person will lead to an additional CV risk „over 
and above the sum of the risks associated with each abnormality” (Golden et al, 2002). 
Thus, it is necessary:  
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- to define and validate a „single, universally accepted diagnostic tool”; 
- to adopt a „global and practical consensus” for using a single “adequate terminology 
that will guarantee the correct understanding of the etiopathogeny, morphological and 
metabolic substrate of the multiple complex phenomena of cardiometabolic syndrome”; 
- to realize a comprehensive “platinum standard” list of criteria, which could be easily 
used in clinical practice and be sufficiently comprehensive in the following clinical 
trials. 
 
CLINICAL SYNDROMES ASSOCIATED WITH INSULIN RESISTANCE 
Type 2 diabetes 
CVD 
Essential hypertension 
Polycystic ovary syndrome 
Nonalcoholic fatty liver disease 
Certain forms of cancer 
Sleep apnea 
Table 4. Clinical syndromes associated with insulin resistance 
4. Etiopathogeny of dysmetabolic syndrome  
Endothelial dysfunction (ED) is a key event in the pathogenesis of atherosclerosis. The 
possibility of early identification of individuals at risk and achieving an objective control of 
the effectiveness of treatment in clinical practice become an attractive goal of therapeutic 
strategies useful to reduce cardiovascular morbid-mortality, and the endothelium is the 
logical “window” for the next evolution of atherosclerosis. 
Given that DMS includes „an atherogenic dyslipidaemia, an insulin resistance state leading 
to a disturbed plasma glucose/insulin homeostasis, a abdominal obesity, especially visceral 
obesity, a thrombotic and inflammatory profile, as well as an endothelial dysfunction could 
substantially increase the risk of coronary heart disease (CHD) and type 2 diabetes” 
(Alexander et al., 2003; Kahn R, et al., 2005; Grundy, 2006). 
K. Watson draws attention to the practicality of cardiometabolic risk management, 
particularly attractive to lower morbidity and mortality but also the economic costs for 
health, particularly if the disease or diseases and/or it’s complications are identified early, 
especially in the subclinical phase (Watson, 2007). 
The key to identification of cardiometabolic risk is the recognition that a patient with one or 
2 clinically evident risk factors likely has additional factors, as these risk factors have been 
shown to „cluster”; this cluster effect is not specific for DMS; it remains a concept on the 
basis of which the results of future research will show new perspectives. 
Meigs et al. refined the concept of the metabolic syndrome “by outlining the function of 
distinct clusters of risk factors”, actually “three factors underlie the clustering of risk 
variables”, risk factors that are still topical:  
1. a "metabolic" factor, including BMI, waist circumference, 2-hour glucose tolerance, 
triglycerides, insulin sensitivity, and plasminogen activator inhibitor;  
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2. an "inflammation" factor, including BMI, waist circumference, fibrinogen, C-reactive 
protein, and insulin sensitivity ; and  
3. a "blood pressure" factor, including systolic and diastolic blood pressure)” (Meigs et al., 
1997). 
Wilcox, presenting the much-disputed „Z syndrome” still in the concept of „cluster”, 
cautions that „in populations at risk of vascular disease, many patients who experience a 
cardiovascular event either do not have identifiable risk factors or have disease severity 
which appears to be out of proportion to their known risk factors. Since these risk factors 
have been shown to be independent predictors of adverse events, they will show at least 
additive effects in combination and possibly potentiate each other” (Wilcox et al., 1998). 
The metabolic syndrome „is a cluster of the most dangerous heart-attack risk factors: 
• diabetes and pre-diabetes, 
• abdominal obesity, 
• high cholesterol and 
• high blood pressure”. 
The clustering of CVD risk factors that marks the metabolic syndrome is now considered to 
be „the driving force for a CVD epidemic” (Stern et al., 2004). 
The exact mechanisms of the complex syndrome are not yet completely known and 
elucidated. Presently, the main etiologic factors for DMS obesity and the dysfunctional 
adipose tissue are present in clinical situations determined by insulin resistance; this process 
also „prevents the efficient conversion of food into energy because of a vastly reduced 
number of insulin receptors on the cell wall”, thus inducing „an increase in blood levels of 
insulin”. In addition, there is a multiple „set of risk factors” that commonly appear together 
in MS, but confer „a substantial additional CV risk, over and above the sum of the risks 
associated with each abnormality” (Golden et al., 2002). 
The etiopathogenesis of the DMS is not entirely known and understood.  
There are three potential etiological categories: obesity and disorders of adipose tissue, 
insulin resistance and a number of independent factors that mediate specific components of 
the DMS; 
It is an established fact that “all components of metabolic syndrome are strongly 
interconnected and so they cannot be treated separately”.  
Questioning if and when “the whole is greater than the sum of its parts?” and „what factors 
comprise the syndrome?”, Kahn argue with several answers: 
- „diagnosing the metabolic syndrome adds nothing beyond each individual risk factor 
for predicting cardiovascular disease or diabetes”; 
- „the definition should include all the factors clearly associated with that underlying 
pathophysiology, such that there is little ambiguity regarding the etiology of the 
clustering”; 
- “if the etiology is unclear, it becomes much more difficult to decide what factors to 
include in the definition, since the word "cluster" itself can be ambiguous” (Kahn et al., 
2005). 
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There is debate “whether obesity or insulin resistance are the causes of the DMS or if they 
are consequences of a more far-reaching metabolic derangement”.  
The multiple risk factors represent factors of metabolic origin, and can be grouped in several 
syndromes, each of which are metabolic risk factors; 
Both insulin resistance and central obesity are considered significant factors. It is necessary 
to specify that insulin resistance is not synonymous with type 2 diabetes mellitus. Insulin 
resistance is not a disease, but remains the “primary mediator of metabolic syndrome”. 
Insulin resistance does not necessarily lead to the clinical syndromes or to obesity; obesity is 
a „physiologic variable that increases the likelihood that an individual will be insulin 
resistant”. It appears long before the diagnosis of diabetes and suggests an increased risk for 
the latter. Unlike type 2 diabetes, in the case of insulin resistance, the pancreas produces too 
much insulin as a compensatory mechanism and does not require drug treatment, but only 
diet and exercise. The combination of insulin resistance with compensatory 
hyperinsulinemia will determine an increased risk for CVD (table 4, 5) (Nakamura et al., 
1994; Nesto, 2003, Matsuzawa et al., 2002). Present studies maintain „the central obesity and 
insulin resistance” as „main etiological factors” in DMS (Matsuzawa et al., 2002). 
 
Fasting insulin 
(Insulin Assay): 
10 IU/mL and below is optimal;  
over 10 IU/mL is high. 
High sensitive CRP 
(C-Reactive Protein): 
Less than 1.0 μU/ml is optimal. 
 
Triglycerides: 50-100 mg/dL is optimal, 
100-150 mg/dL is moderate 
and over 150 mg/dL is high. 
Homocysteine: Less than 6 μmol.L is optimal; 
greater than 9 μmol/L is high.
Cholesterol: HDL 40 mg/dL is good, although higher is even better. 
In studies, women with HDL of 70 mg/dL had low 
cardiac risk. 
LDL of less than 100 mg/dL is good. 
Total cholesterol should be less than 200 mg/dL or 
under. 
Fasting glucose: Normal is 74-106 mg/dL.
Values of 100-125 mg/dL are indicative of Pre-Diabetes. 
Values greater than or equal to 126 mg/dL are 
indicative of Type 2 Diabetes.
Oral glucose tolerance 
(with 75 gr. Glucose load): 
Results greater than or equal to 200 at 2 hours following 
the oral glucose tolerance test indicate Type 2 Diabetes. 
(PAI -1): Greater than 31
Fibrinogen: This test is a general measure of inflammatory 
processes; the results vary greatly with the patient’s 
age, gender and test method. Results that are both too 
high and too low are problematic.  
Table 5. Lab exams in DMS (Grundy et al., 2005) 
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4.1 Central obesity 
It has been demonstrated that the central obesity is by far the most prevalent form of the MS 
and a major component of the MS. Reaven points out that insulin resistance does not cause 
obesity; rather, obesity causes insulin resistance and has a key role in the pathophysiology 
of metabolic disorders; but insulin resistance also occurs in 10% to 15% of people who are 
not overweight. Basically, abdominal (visceral) obesity: 
- represents the accumulation of central fat,  
- plays a key role in the pathophysiology of metabolic disorders,  
- has potential negative effects on metabolic and CV risk, 
- is associated with insulin resistance, but is independently associated with each of the 
other MS components, including insulin resistance, 
- predicts the development of type 2 DM, 
- is easily measured, either by waist circumference or by waist-to-hip ratio; 
- this measurement estimates the CV risk (table 3) 
- has “remarkable heterogeneity”(Weisberg et al., 2003; Nesto, 2003; Grundy et al., 2005). 
These affirmations are sustained by the following arguments: 
- there is a linear correlation between waist circumference and visceral fat; but, 
subcutaneous fat is metabolically and cardiovascularly inert, exerting a possible 
protective function;  
- insulin resistance of visceral fat is linked to dislipidemia, hypertension, hyperglycemia 
and inflammation, complex phenomenon representing DMS ; 
- adipocyte (fat cells of the visceral fat) dysfunction may be either „intrinsic or secondary 
to immune dysregulation, inflammation, hypothalamic-pituitary adrenal dysfunction, 
local glucocorticoid dysregulation within visceral fat, or, possibly, stress or energy 
imbalance”; adipocytes hypertrophy is followed by macrophage infiltration, 
inflammation, and so on, with the alteration of different functions (TNFα, resistin, PAI-
1, etc.), which contributes to a prothrombotic state; 
- hypoadiponectinemia has been shown to increase insulin resistance, and is considered 
to be a risk factor for developing and worsening MS; 
- the visceral, abdominal fat tissue releases inflammatory cytokines that increase insulin 
resistance in the body’s skeletal muscles, and is also associated with a decreased 
production of adiponectin, which is the adipose-specific, collagen-like molecule with 
anti diabetic, anti-atherosclerotic and anti-inflammatory functions; 
- TNFα presence can increase production of inflammatory cytokines and may lead to 
insulin resistance during a very complex process. (Grundy et al., 2004; Matsuzawa et al., 
2004a, 2004b). 
The distribution of adipose tissue appears to affect its role in metabolic syndrome. While 
visceral, intra-abdominal fat correlates with inflammation, subcutaneous fat does not. Only 
abdominal fat produces potentially harmful levels of cytokines (tumor necrosis factor, 
adiponectin, leptin, resistin, and plasminogen activator inhibitor). Only visceral fat 
accumulation and insulin-resistance have been associated with a cluster of dyslipidaemic 
features (i.e., elevated plasma triglyceride, increased very low density lipoprotein /VLDL, 
presence of small dense LDL particles, with decreased of HDL-cholesterol, and so on).  
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In conclusion, central obesity: 
1. is independently associated with each of the other metabolic syndrome components, 
including insulin resistance 
2. contributes to hypertension, dyslipidemia (high serum cholesterol, low HDL-c) and 
hyperglycemia, and is independently associated with higher CVD risk. (Anderson et al., 
2001; Zimmet et al., 2001). 
The increased flow of free fatty acids through the liver leads to accelerated synthesis of 
VLDL-C, hypertriglyceridemia, endothelial dysfunction, and vasoconstriction, leading to an 
increase in blood pressure; also, through this mechanism, insulin resistance may exert an 
atherogenic effect (Fonseca, 2005). 
4.2 Inflammation 
A number of markers of systemic inflammation, including C-reactive protein, are often 
increased, as are fibrinogen, interleukin 6 (IL–6), tumor necrosis factor-alpha (TNFα), and 
others. 
CVD and diabetes are associated with elevated levels of inflammatory biomarkers, 
including C-reactive protein (CRP).  
At the same time, CRP is the best-studied inflammatory marker of atherothrombotic risk, 
placed among the parameters used in “Framingham Risk Score”. 
C-reactive protein is present in the MS; its plasma levels increase with the number of 
metabolic risk factors, and also with other inflammatory markers; these associations are 
„purely correlative, not causative, and do not imply a mechanistic action” (table 2)  
The mechanisms that lead to the increase of CRP are complex and only partially understood; 
we take this opportunity to remind that only excessive fatty tissue releases inflammatory 
cytokines and determines higher CRP levels; adipose cell enlargement and infiltration of 
macrophages into adipose tissue will lead to the release of proinflammatory cytokines and 
promote insulin resistance. It increases the thrombogenicity of circulating blood, in part by 
raising plasminogen activator type 1 and adipokine levels, and it causes endothelial 
dysfunction (Grundy et al., 2004; Ridker et al., 2004). 
4.3 The prothrombotic and proinflammatory states 
The prothrombotic and proinflammatory states may be metabolically interconnected by 
“plasma plasminogen activator inhibitor (PAI)-1 and fibrinogen”, “in response to a high-
cytokine state” (Grundy et al., 2004) 
4.4 Atherogenic dyslipidemia 
Atherogenic dyslipidemia represents the combination of raised triglycerides (TG), low HDL-
C, elevated apolipoprotein B (ApoB), small dense LDL and small HDL particles, and so on; 
all are independently atherogenic and are observed in type 2 DM and DMS. Low HDL-c is 
considered to be „a particularly key risk factor for CVD in both non-diabetic and diabetic 
individuals”, „an independent contributor to CVD, in both men and women”. Low HDL-c 
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and high TG levels are frequently found in insulin resistance, with or without type 2 
diabetes, and both are risk factors for CVD (table 3) (Robins et al., 2003; Brunzell & Ayyobi, 
2003). 
5. Diagnosis of DMS 
Although the present review does not have as purpose the detailed presentation of the way 
in which the diagnosis of DMS is made, we consider that few remarks are necessary in order 
to manage it correctly.  
The literature of the past years regarding the management of this concept agrees upon the 
necessity of a team research, especially in the population of high risk, on national criteria, 
with subsequent establishment of a realistic management programme.  
S Julius (and not only him) supports this point of view because “the clinical spectrum of the 
Metabolic Syndrome is variable and influenced by gender, ethnicity, and genetic 
susceptibility”, especially in arterial hypertension, and even in borderline hypertension 
(Julius & Nesbitt, 1996). Paul Zimmet, from Australia, draws attention to the need of a 
“careful definition and management of the “tick test” in the DMS”, which must rely on 
„evidence-based criteria”; he adds: “Tackling diabetes and obesity is likely to be the single 
most important challenge for Australia’s public health in the 21st century. It is a battle that 
we can and must win!” (Eckel et al., 2005; Barr et al., 2006). More recently, a Joint Scientific 
Statement was necessary “in an attempt to unify criteria”, to underline the fact that DMS is a 
“multifaceted, but distinct entity”, and that “further progress depends in part on 
interdisciplinary dissemination of knowledge” (Table 6); moreover, “various diagnostic 
criteria have been proposed by different organizations over the past decade”, which often 
led to confusion.  
Simmons RK and collaborators evaluated the utility of metabolic syndrome from several 
points of view: pathophysiology, epidemiology, clinical work and public health, but also 
educational; the authors conclude that they agree with this „concept that focuses attention 
on complex multifactorial health problems”, but they accept it only as „a diagnostic or 
management tool” with a limited practical utility (Simmons et al., 2010). 
To gave up the widespread term of DMS that Sindrom metabolic, which is used for many 
years for this „cluster of risk factors”, “ is an unrealistic act, even impossible to fulfill, 
because the term is rooted in the medical literature”; DMS is: „a heterogeneous entity, 
composed of abnormal situations involved in the production of a metabolic imbalance with 
common metabolic links, but also with important differences in the etiopathogenesis of its 
components” (Balta, 2010). 
Despite numerous criticisms of the concept by many authors, Kahn and collegues express 
„our recommendations to clinicians”: 
„All CVD risk factors should be individually and aggressively treated” 
„Pharmacological therapy to reduce insulin resistance will be beneficial to patients with the 
metabolic syndrome” 
„An aggressive research agenda to identify the underlying cause(s) of the CVD risk factor 
clustering”  
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…”it remains to be demonstrated that the impact of the syndrome exceeds that of the sum of 
its individual components” and so on (Kahn et al., 2005). 
David Nathan (Massachusetts General Hospital, Boston) described the situation as "a 
firestorm about nothing" and adds about DMS: 
- “it was raised from a research view”,  
- “it captured a confluence of clinical conditions that can occur together” 
- “an important concept from an epidemiology view and to investigate whether these 
conditions had a single underling cause”. 
 
Hypertriglyceridaemic waist phenotype
estimated prevalence: 20-25% 
- Atherogenic metabolic triad (fasting hyperinsulinaemia, elevated apolipoprotein B levels 
and increased proportion of small LDL particles 
- Elevated total cholesterol/HDL cholesterol ratio 
- Postprandial hyperlipidaemia 
– Fasting hyperinsulinaemia 
– Glucose intolerance 
– Increased risk of type 2 diabetes 
– Increased cardiovascular risk 
Table 6. Hypertriglyceridaemic waist phenotupe association with features of metabolic 
syndrome 
We note some compelling conclusions regarding the current global state of DMS:  
-  “DMS is common and it has a rising prevalence worldwide. 
- Now, DMS is both a public health and a clinical problem. 
- The DMS is a complex of interrelated risk factors for CVD, DM. 
- Three abnormal findings out of 5 would qualify a person for the metabolic syndrome. 
- The term “metabolic syndrome” is acceptable for the condition of the presence of 
multiple metabolic risk factors for CVD and DM. 
- The metabolic syndrome is not an absolute risk indicator. 
- The metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and 
elevated plasma glucose. 
- The risk associated with a particular waist measurement will differ in different 
populations. We recommend the use of waist measurement as a useful screening tool in 
many primary populations”(Alberti et al., 2009). 
Even if now we assign to DMS multiple metabolic risk factors and/or a complex of 
interrelated risk factors for CVD and DM, although we know that DMS substantially 
increases the risk of CHD, we do not know which of its defining characteristics (insulin 
resistance/ hyperinsulinaemia, small LDL particles, reduced adiponectin levels, increased 
CRP, etc.) are “critical therapeutic targets for the optimal management of CHD and type 2 
diabetic risk” (Hu et al., 2001). We need to globally asses the individual risk of these patients 
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in order to optimally manage the dyslipidaemic state in this high-risk population. In the 
context of the current knowledge regarding the DMS, the patients diagnosed with arterial 
hypertension, DLP, or hyperglycemia will be actively investigated for DMS. We must insist 
upon the realisation of a complete diagnosis, specifying the risk score for CV and/or 
metabolic disorders that we found (table 5, 6).  
Given the susceptibility to many other pathological conditions, we must use all clinical and 
paraclinical methods needed in order to establish a positive and differential diagnosis (ex. 
polycystic ovary syndrome, fatty liver, cholesterol gallstones, asthma, sleep disturbances, 
some forms of cancer), especially if they are sugested by the familial genetic aspect, by the 
signs and simptoms and so on. The mesurement that are needed (weight, height, waist 
circumference or waist/hip ratio) for initial diagnosis of DMS and for follow-up will be 
taken in a proper manner, following the current guidelines (by gender, etnicity, etc.). It is 
estimated that the introduction of “waist circumference rather than the body mass index has 
been “a major conceptual leap”, because it recognizes the much greater causal role of 
abdominal obesity than general obesity. (www.metabolicsyndromeinstitut/information 
/screeningdiagnosis/procedures-for-the-measurement-of-the-waist-circumference.php).  
The canadian researchers Lemieux I, Pascot A, Couillard C et al., introduce a new notion, 
namely: „HYPERTRIGLYCERIDEMIC WAIST”: a marker of the atherogenic metabolic triad: 
hyperinsulinemia, hyperapolipoprotein B, and small, dense LDL, in men. We note the depth 
of this interesting concept, its validation in a trial (Que囲bec Health Survey) and its practical 
usefulness, at least from two points of view:  
- first, the possibility of identifying men at high risk, with normal glucose levels or 
impaired fasting glucose state; 
- secondly, because it avoids the exact procedure for measuring visceral fat by 
sophisticated and costly methods, such as magnetic resonance or computed 
tomography. 
„The hypertriglyceridaemic waist phenotype significantly increased the odds of finding 
CAD in men, whereas impaired fasting glucose was not predictive of CAD in the absence of 
hypertriglyceridaemic waist”: 
- “the simultaneous measurement and interpretation of waist circumference and 
triglyceride level”, "the hypertriglyceridaemic waist", may be a simple tool to identify 
individuals at high risk”; 
- “men characterised by the hypertriglyceridaemic waist phenotype had a substantially 
elevated total cholesterol/HDL-cholesterol ratio compared with those without this 
phenotype”; 
- results suggest that the hypertriglyceridaemic waist phenotype may be useful in the 
screening of patients with many features of DMS (Table 7), such as an elevated total 
cholesterol/HDL-cholesterol ratio, postprandial hyperlipidaemia, fasting 
hyperinsulinaemia and additional risk factors. 
Identified by the simultaneous measurement of waist circumference and fasting triglyceride 
levels, this approach can be “a simple and inexpensive marker to better identify individuals 
at high risk of CVD and/or type-2 diabetes and to evaluate CHD risk in individuals with 
abdominal obesity”(Lemieux et al., 2002; Blackburn et al. 2003). 
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There are multiple laboratory tests and many of them are vital (glycaemic profile, lipids, 
inflammatory tests); we must not forget about exploring the thyroid function or 
investigating other systems (cerebrovascular, hepatic or renal). The new guidelines 
recognize the importance of elevated triglycerides and of reduced HDL cholesterol 
concentrations as useful lipid markers of the presence of an atherogenic "dysmetabolic" 
milieu. In DMS, the lipidic profile can vary, and so can the therapeutic options; they can be 
prescribed together with dietary changes or sustained physical effort.  
Here are a few patterns:  
- when there is a high LDL-cholesterol level, the use of statins as the drug of choice is 
preferred to reduce the risk of a first or recurrent CHD event;  
- if we have a “normal” LDL-cholesterol level and typical dyslipidaemia, a fibrate is 
preferred as the first therapeutic option; 
- if LDL-cholesterol and triglycerides are elevated, together with a relatively low HDL-
cholesterol, patients are considered under “high risk” and combination therapy with 
both a statin and a fibrate is indicated, because of the high risk atherogenic profile - 
“atherogenic dyslipidemia” (Sacks, 2002).  
Interventions which can improve insulin sensitivity, especially lifestyle modifications, 
weight loss, Mediterranean diet, and increased physical activity, remain the elements of 
choice in DMS, because of their favorable impact on DMS components. (Hu et al., 2001) 
As an example for the complexity of what we call DMS, Zeller, Steg et al. insist that “fasting 
hyperglycaemia is the most important risk factor for development of severe heart failure in 
patients with metabolic syndrome”; these situations are associated with „a higher in-
hospital case fatality rate”; strict control of glycemic levels in patients with DMS with or 
without a critical state is recommended by many authors and by the algorithm of the 
American Diabetes Association and the European Association for the Study of Diabetes 
(2006) (Zeller et al. 2005; Nathan et al., 2006). 
Similarly, for a correct and complete diagnosis, Enzo Bonora et al. proposed a short list of 
novel (non-traditional) risk factors in order to emphasise the fact that, in the “metabolic 
syndrome approach”, it is necessary to prove the “existence of underlying pathogenic 
disorders of the cluster, i.e. central obesity and insulin resistance”; to this end, the authors 
present a “systematization of biomarkers” that are useful in DMS and in clinical trials:  
- chronic mild inflammation (e.g. C-reactive protein, CRP, white blood cells, WBC, 
erythrocyte sedimentation rate, ESR),  
- increased oxidant stress (e.g. oxidized LDL, reactive exigent species, ROS),  
- thrombophilia (e.g. fibrinogen, plasminogen activator inhibitor-1, PAI-1), - endothelial 
dysfunction (e.g. E-selectin, intercellular adhesion molecule-1, ICAM-1,  
- vascular cell adhesion molecule-1, VCAM-1), 
- adipose tissue derangement (e.g. adiponectin, leptin, resistin). 
The authors consider that a better diagnosis and treatment of “several classic and ancillary 
components of the metabolic syndrome” will accomplish ”a substantial reduction of the 
cardiovascular risk” (Bonora et al., 2003). 
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Matsuzawa Y, Funahashi T, and many others emphasize the importance of adiponectin; 
“one of these adipocytokines which we identified in human adipose tissue”; it circulates 
abundantly in human plasma, and has both anti-atherogenic and anti-diabetic effects. In 
addition, a series of clinical and experimental studies suggest that adiponectin may become 
a novel ‘hot’ marker of the Metabolic Syndrome (Matsuzawa et al., 2004).  
Based on complicated lab research, Kumada M, Kihara S, Ouchi N et al. suggest the results 
above and conclude that „plasma adiponectin may become a novel biomarker for 
atherosclerotic vascular diseases, as well as plasma cholesterol and glucose levels” (Kumada 
et al., 2004). 
The significance of adiponectin as „a negative risk for diabetes and its dual protective 
capacity”, both against diabetes and atherosclerosis, makes the subject of much prestigious 
research; we are talking about „adipocytokines”, considering the remark that “reduction of 
adiponectin may facilitate coronary plaque rupture” but, at the same time, adiponectin 
„suppresses both the atherosclerotic process and the production of an inflammatory 
cytokine,” and so on.  
Based on all these observations, it is obvious why „body weight reduction, physical exercise, 
and lifestyle changes” can raise plasma adiponectin levels. In addition, agents such as 
“thiazolidinediones, renin-angiotensin system blockers and glimepiride” have been 
reported to increase adiponectin concentrations (Weyer et al., 2001). 
Wiecek et al. reported that plasma adiponectin levels are negatively correlated with mean 
blood pressure (BP) in patients with essential hypertension (Adamczak et al., 2003). 
Some well known Japanese authors point out the association of obesity with increased risk 
for breast and endometrial cancers; also, high serum adiponectin levels are associated with 
an increased risk for breast cancer (Miyoshi et al., 2003). 
Imaging tests are not routinely indicated, but they can be performed when previous 
examinations suggest cardiovascular complications.  
Adverse clinical consequences and/or target organ damage appear during long term 
evolution of DMS; all these elements will be periodically investigated and quantified by 
specific methods. The most frequent example is represented by arterial hypertension, which 
evolves with very important target organ damage (left ventricular hypertrophy, progressive 
peripheral arterial disease, and renal dysfunction). 
Using the NCEP/ATP III definition, Mulè et al. investigated the efect of SXM on markers of 
target organ damage, and they have demonstrated that these lesions can explain „the 
enhanced cardiovascular risk associated with the Metabolic Syndrome”. The authors also 
conclude that there must be a global evaluation of the „influence of the SXM on some 
cardiac, renal, and retinal markers of target organ impairment” (Mulè et al., 2005). 
We must not overlook the complications associated with DMS, representing short and long-
term prognosis factors; there can be cardiovascular (coronary heart disease, atrial 
fibrillation, heart failure, aortic stenosis , ischemic stroke, and so on) or extra cardiac 
complications (nonalcoholic fatty liver disease, obstructive sleep apnea, breast cancer, cancer 
of the colon, gallbladder, kidney, prostate gland, and so on). 
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6. Management of DMS  
Because DMS is associated with dramatically higher risk of DCV, diabetes, and so on, its 
recognition and follow-up have become a major issue in preventive cardiology.  
According to the DMS concept and the recognition of its defining combinations 
(hypertriglyceridemia, hyperglycemia, hypertension, low HDL-C level, and greater waist 
circumference /adiposity) there are: 
- a clinical method for identifying CVD risk and symptoms of an underlying disease or 
condition; 
- the variation of cardiovascular and metabolic risk according to which syndrome 
components are present, their duration, and existing complications.  
These elements represent the foundation of DMS complex management. (Ding et al., 2010).  
6.1 Primary prevention  
Primary prevention consists in a healthy life style, smoking cessation, caloric restriction, and 
a modified daily diet. A moderate increase of physical activity and a 7-10% weight loss over 
6-12 months are also indicated. 
Low caloric diet and moderate but sustained exertion are considered “the most important 
initial steps in treating metabolic syndrome” (Ford et al., 2002). 
If we analyze each individual component of DMS reporting it to the DMS diagnosis, a 
greater chance of progression was observed, especially if we consider that hyperglycemia, 
hypertension, and low HDL-C level are the main risk factors; consequently, these risk 
factors represent a potential target for active and individual cardiovascular prevention in 
these patients (Després et al., 2008). 
6.2 Secondary prevention 
Secondary prevention is addressed to patients for whom lifestyle change is not enough and 
who are considered to be at high risk for CVD; these patients will receive medical treatment 
together with lifestyle changes.  
All these will act “as a whole” on the basic mechanisms of DMS in order to reduce the 
evolutionary impact of all risk factors and all “metabolic and cardiovascular consequences”, 
on short and long-term evolution.  
Separate, incomplete or inconsistent approach of individual components of DMS is to be 
avoided; the emphasis will be laid on sustained reduction of individual risk, especially in 
patients with several DMS components and complications; only, in this way, we can really 
reduce „the overall impact on CVD and DM risk”. (Lindström et al., 2003; Tuomilehto et al. 
2001). 
After the complete diagnosis is established, the management of DMS must be more 
comprehensive and more aggressive compared to other clinical situations, in order to 
reduce the risk for CVD and DM; thereby, a complete evaluation of cardiovascular risk 
according to present guidelines of medical practice is of outmost importance.  
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Framingham risk scoring (or other risk scores, although they include different components) 
will be used to estimate „10-year atherosclerotic disease risk” and may guide the use of 
medication therapy (Spellman & Chemitiganti, 2010; Nicholls et al., 2007). 
6.3 Medical care 
The initial management of metabolic syndrome involves lifestyle modifications (changes in 
diet and exercise habits).  
The choice of drug and dose should be individualized to the patient and titrated to achieve 
guideline-recommended goals. 
Diets that promote the consumption of fruits, vegetables, and low-fat dairy products 
(“DASH-style diet”) help lower blood pressure and may lower risk of stroke. The 
consumption of products with high-glycemic-index will be avoided. 
Increasing physical activity is associated with a reduction in the risk of stroke, at least 30 
minutes of moderate intensity activity on a daily basis, maintaining long-term adherence. 
Weight reduction among overweight and obese persons is recommended to reduce blood 
pressure and risk of stroke.  
Bianchi C et al. stipulates the basics of food diet for prevention and treatment of DMS:   
- protein for 10-20% of total daily energy;  
- saturated fatty acids and trans-unsaturated fatty acids ≤ 10% of total energy, and 
further lowered to < 8%, if serum LDL-cholesterol level is increased;  
- cholesterol intake: 300 mg or less per day;  
- carbohydrates: 45-60% of total energy, vegetables, legumes, fruits, and whole-grain 
cereals: the most appropriate sources of carbohydrates; 
- foods rich in dietary fiber: ≥ 40 g/d (or 20 g/1000 kcal/d), about half in soluble form;  
- sodium restriction can reduce systolic blood pressure in hypertensive patients; 
- 30 minutes of walking a day: all overweight subjects;  
- pharmacotherapy may be necessary for cardiovascular risk factors: LDL-cholesterol, 
hypertension, T2DM, and obesity (Bianchi et al., 2006). 
The medical care is represented by “a multi-drug treatment”, in order to reduce morbidity 
and prevent DMS complications; the treatment must be with metabolic and glucidic 
neutrality, with respect to the accompanying disturbances of the DMS”: 
- angiotensin converting enzyme inhibitors (ACEI) or/and angiotensin-II-receptor blockers; 
- anti-diabetic treatments to improve glycemic control, with metformin and 
thiazolidinediones, representing “a rational first-line treatment of patients with type 2 
diabetes mellitus ”; 
- obesity and visceral obesity can respond to certain drugs with “the potential possibility 
of ameliorating the metabolic aspects in obese patients”: Sibutramine, Orlistat and 
Rimonabant (the first inhibitor of CB1 receptors); 
- although a therapeutic class of drugs capable of reducing the “inflammatory state” from 
DMS has not been established, there are many classes of drugs indicated in these 
patients (statins, fibrates, ACEIs, and thiazolidinediones), with an anti-inflammatory 
action; 
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- the procoagulative state in these patients, associated with elevation of the circulating 
levels of fibrinogen, factor VII, PAI-1, together with an increased platelet aggregation, 
determine the introduction of low-dose aspirin, with or without other anti-
inflammatory agents (Antithrombotic Trialists’ Collaboration, 2002). 
In dyslipidemia, primary aims for therapy are: 
1. lower TG (as well as lowering ApoB and non-HDL cholesterol), 
2. raise HDL-c levels, 
3. reduce LDL-c levels (elevated levels represent a high risk in the metabolic syndrome). 
Fibrates (PPAR alpha agonists) improve all components of atherogenic dyslipidaemia 
(elevated triglyceride and low HDL-C levels), especially in overweight patients, and reduce 
the risk for cardiovascular disease in DMS, 
For patients with elevated triglyceride levels, the addition of omega-3 fatty acids is likely to 
produce added benefit (according to clinical trials). 
Statins are administered in order to reduce all apoB-containing lipoproteins and to achieve 
ATP III goals for LDL-cholesterol, as well as for non-HDL-Cholesterol; the multiple benefits 
are confirmed through many clinical trials „at all indicated ranges”, the pleiotropic and 
metabolic effects being an ”undisputed reality”. 
Management of reduced high-density lipoprotein cholesterol (HDL-C) remains 
controversial, not yet having a specific treatment; some measures have proved a positive 
influence: dietary changes, sustained physical efort, some statins (ex. Rosuvatatin), etc.  
The latest guidelines insist on LDL-cholesterol being „the primary target of treatment by 
adequate use of statins”; although high levels of LDL-cholesterol are not necessarily 
associated with DMS, they will be properly quantified and treated, for reducing the 
cardiovascular risk.   
Fibric-acid derivatives, bile acid sequestrants, and ezetimibe may be useful in patients who 
have not achieved target LDL with statin therapy or cannot tolerate statins (Eckel et al., 
2005; Alberti et al., 2009; Robins et al., 2003; Heart Protection Study Collaborative Group, 
2003; The Task Force for the management of dyslipidaemias of the European Society of 
Cardiology (ESC) and the European Atherosclerosis Society 2011). 
Hypertension remains a clinical target according to present guidelines; regular blood 
pressure screening, lifestyle modification, and drug therapy are recommended. The focus 
must be on clinical situations associated with target organ damage, diabetes, or renal 
complications. Hypertension and diabetes, both components of metabolic syndrome, are 
known to be associated with renal dysfunction; oxidative stress and inflammation mediated 
by renin-angiotensin system activation are the most frequently involved mechanisms. Other 
mechanisms acting singly or in combination, linking obesity to chronic kidney disease, have 
been proposed: renal adaptation to increased body mass, with an increased excretory load, 
sodium retention, insulin resistance, renal lipotoxicity, etc. (Praga, 2002).  
Microalbuminuria, however, was more common in subjects who had a constellation of all 3 
components of metabolic syndrome than in those without. Presently, microalbuminuria is 
an early marker of renal dysfunction due to hypertension, predicts the onset of kidney 
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disease in diabetic and nondiabetic subjects, and reflects widespread endothelial 
dysfunction, microvascular damage, and possibly inflammation. (Gerstein et al., 2001; Festa 
et al., 2000). The precise pathogenetic basis of microalbuminuria in metabolic syndrome is 
not known; it is, however, possible that microalbuminuria in metabolic syndrome reflects 
renin-angiotensin system activation and resultant oxidant stress, inflammation, and 
endothelial injury. 
Dzau VJ, Safar ME, amongst many other elite scientists, have shown that hypertension, 
dyslipidemia, and insulin resistance are associated with renin-angiotensin system activation 
and generation of large amounts of angiotensin II (Dzau & Safar, 1988; Shinozaki et al., 2004).  
Angiotensin converting enzyme inhibitors and angiotensin receptor blockers are useful 
antihypertensive drugs; some clinical trials suggest that they have advantages over other 
drugs, in patients with diabetes, and that the risk reduction associated with 
antihypertensive drugs is „the result of blood pressure lowering per se, and not due to a 
particular type of drug” (Chobanian et al., 2003). 
Diabetes mellitus, recognized as „a true cardiovascular disease”, raises particular problems 
of follow-up and treatment; the periodic screening with the assessment of end-organ 
complications is required even from the beginning of its evolution; 
- the sustained control of blood pressure and dyslipidemia, along with diet, regular 
physical exercise, and the maintaining of normal body weight is recommended; 
- as in hypertension, for DM, medical practice guidelines come with many details for 
each of „these pursue matters” (ex. JNC 7, update 2009). 
Medical treatment of hyperglycemia in DMS begins with an insulin-sensitizing agent (ex. 
metformin), which proved that it can reverse the complications DMS, especially together 
with fibrates and thiazolidinediones. 
Multiple research have shown the possibility that drugs that reduce insulin resistance will 
delay the onset of type 2 diabetes and will reduce CVD risk, when DMS is present (ex. 
„Diabetes Prevention Program” (DPP) with metformin, thiazolidinedione in delaying or 
preventing type 2 diabetes in impaired glucose tolerance (IGT) and insulin resistance) 
(www.idf.org). 
Of course, we should not avoid prescribing aspirin for its well-deserved preventive actions, 
especially in patients with a high CV risk given by DMS, unless contraindicated.  
Many other recommendations are necessary: 
- patients with diabetes should be referred to a diabetic nutritionist, if not an 
endocrinologist; 
- patients with high CV risk should be referred to a cardiologist for primary or secondary 
prevention of CVD; 
- patients who are at high risk for obesity-associated morbidity and mortality with BMI 
greater than 40 kg/m2 or with BMI >35 kg/m2 plus one or more significant co-morbid 
conditions may be referred for consideration of bariatric surgery, when less invasive 
methods of weight loss have failed, etc., for more than 5 years; 
- liposuction is used for cosmetic weight loss, but evidence shows that liposuction of 
abdominal subcutaneous fat (with no removal of visceral fat) has little effect on 
cardiometabolic risk parameters. 
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Moreover, it is required to follow up the effect/effects of the prescribed treatment, 
especially in cases of hypertension, DLP and DM, with a periodic assessment of patient 
adherence to treatment; attention will be directed to prescribe optimal combination 
regimens, respectively those recognized in reducing the CV risk. 
Of course that the management of DMS is impossible to be wholly presented; it is a subject 
of great practical interest, but its defining elements are found in specialized literature and 
guides. 
7. Conclusions 
With all these questions, different opinions and debates, “the metabolic syndrome serves as 
a call to action for practitioners to focus more carefully on risk prevention above and beyond 
traditional …”. (Smith, 2006). 
Jean Pierre Després (Institut Universitaire de Cardiologie et de Pneumologie de Québec) 
presents the DMS as "a work in progress" and adds :« I think it should be redefined as a 
constellation of metabolic abnormalities associated with visceral fat and insulin resistance; 
this would simply things and clarify a lot of confusion over this." (Després, 2008) 
DMS was and remains an attractive subject in many ways, theoretical and practical, as 
demonstrated by all of the research so far; it remains a concept with great practical use, a 
heterogeneous entity based on a metabolic imbalance that has not yet found the best 
definition, the optimal nosological framing, widely accepted, even if it will reach soon 100 
years of existence. 
We propose the terminology of CARDIOVASCULAR DISMETABOLIC SYNDROME (CV 
DMS) which express a metabolic disorder, multifactorial entity that require the participation of 
several medical specialties (even over 10 specialities) in order to quantify and consolidate the 
defining elements of cardiometabolic risk and defining appropriate management in real time. 
In order to reduce the confusion in the medical community, universal agreement on the 
definition and clinical tools to assess the DMS would be very helpful and eforts for 
additional international consensus activities have been made; all this research will 
determine all the “preventive and screening strategies for the dismetabolic syndrome”. 
Theoreticians and practitioners, laboratory doctors, lipidologists, diabetologists, 
nutritionists, or hypertensiologists, cardiologists, nephrologists, neurologists, 
endocrinologists, but also pediatricians, geneticists, family doctors and so on all participate 
in this complex process, because only teamwork can, indeed, to define actively, to monitor 
and improve multiple abnormal components of this entity called CARDIOVASCULAR 
DISMETABOLIC SYNDROME (CV DMS). 
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